Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica

Mayank R. Ajmera, Audra Boscoe, Josephine Mauskopf, Sean D. Candrilli, Michael Levy

Research output: Contribution to journalArticle

Abstract

Background Neuromyelitis optica (NMO) is characterized by unpredictable attacks on the optic nerves and spinal cord, causing accumulations of neurological disability that may lead to blindness and paralysis. We examined comorbidities and health care use among patients with highly active NMO, defined as at least two relapses within 12 months of the patient's first NMO encounter in the database. Methods This retrospective study of a US administrative claims database compared patients with highly active NMO to matched individuals without NMO. All outcomes, including Charlson Comorbidity Index (CCI) score, hospitalizations, and emergency department visits, were measured over the 12-month period following the patient's first NMO encounter in the database. Results A total of 1349 patients with NMO were identified. Of these, 134 had highly active NMO (80% female, mean age 45.6 years) and were matched to 670 non-NMO controls. Patients with highly active NMO had significantly greater comorbidity burden than non-NMO controls (mean CCI score: 4.1 versus 0.6; P < 0.0001) and greater proportions of hospitalization (53.7% versus 4.0%; P < 0.0001) and emergency department visits (60.5% versus 9.7%; P < 0.0001). Conclusions High occurrence of several acute and chronic conditions and extensive health care use highlight the significant medical burden among patients with highly active NMO.

Original languageEnglish (US)
Pages (from-to)96-103
Number of pages8
JournalJournal of the Neurological Sciences
Volume384
DOIs
StatePublished - Jan 15 2018

Fingerprint

Neuromyelitis Optica
Health Resources
Comorbidity
Delivery of Health Care
Databases
Hospital Emergency Service
Hospitalization
Blindness
Optic Nerve
Paralysis
Spinal Cord
Retrospective Studies

Keywords

  • Disease burden
  • Neurological disorders
  • Neuromyelitis optica
  • Real-world case-control study

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. / Ajmera, Mayank R.; Boscoe, Audra; Mauskopf, Josephine; Candrilli, Sean D.; Levy, Michael.

In: Journal of the Neurological Sciences, Vol. 384, 15.01.2018, p. 96-103.

Research output: Contribution to journalArticle

Ajmera, Mayank R. ; Boscoe, Audra ; Mauskopf, Josephine ; Candrilli, Sean D. ; Levy, Michael. / Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. In: Journal of the Neurological Sciences. 2018 ; Vol. 384. pp. 96-103.
@article{f84cbb462c9b4ca782c85652258a8093,
title = "Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica",
abstract = "Background Neuromyelitis optica (NMO) is characterized by unpredictable attacks on the optic nerves and spinal cord, causing accumulations of neurological disability that may lead to blindness and paralysis. We examined comorbidities and health care use among patients with highly active NMO, defined as at least two relapses within 12 months of the patient's first NMO encounter in the database. Methods This retrospective study of a US administrative claims database compared patients with highly active NMO to matched individuals without NMO. All outcomes, including Charlson Comorbidity Index (CCI) score, hospitalizations, and emergency department visits, were measured over the 12-month period following the patient's first NMO encounter in the database. Results A total of 1349 patients with NMO were identified. Of these, 134 had highly active NMO (80{\%} female, mean age 45.6 years) and were matched to 670 non-NMO controls. Patients with highly active NMO had significantly greater comorbidity burden than non-NMO controls (mean CCI score: 4.1 versus 0.6; P < 0.0001) and greater proportions of hospitalization (53.7{\%} versus 4.0{\%}; P < 0.0001) and emergency department visits (60.5{\%} versus 9.7{\%}; P < 0.0001). Conclusions High occurrence of several acute and chronic conditions and extensive health care use highlight the significant medical burden among patients with highly active NMO.",
keywords = "Disease burden, Neurological disorders, Neuromyelitis optica, Real-world case-control study",
author = "Ajmera, {Mayank R.} and Audra Boscoe and Josephine Mauskopf and Candrilli, {Sean D.} and Michael Levy",
year = "2018",
month = "1",
day = "15",
doi = "10.1016/j.jns.2017.11.022",
language = "English (US)",
volume = "384",
pages = "96--103",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica

AU - Ajmera, Mayank R.

AU - Boscoe, Audra

AU - Mauskopf, Josephine

AU - Candrilli, Sean D.

AU - Levy, Michael

PY - 2018/1/15

Y1 - 2018/1/15

N2 - Background Neuromyelitis optica (NMO) is characterized by unpredictable attacks on the optic nerves and spinal cord, causing accumulations of neurological disability that may lead to blindness and paralysis. We examined comorbidities and health care use among patients with highly active NMO, defined as at least two relapses within 12 months of the patient's first NMO encounter in the database. Methods This retrospective study of a US administrative claims database compared patients with highly active NMO to matched individuals without NMO. All outcomes, including Charlson Comorbidity Index (CCI) score, hospitalizations, and emergency department visits, were measured over the 12-month period following the patient's first NMO encounter in the database. Results A total of 1349 patients with NMO were identified. Of these, 134 had highly active NMO (80% female, mean age 45.6 years) and were matched to 670 non-NMO controls. Patients with highly active NMO had significantly greater comorbidity burden than non-NMO controls (mean CCI score: 4.1 versus 0.6; P < 0.0001) and greater proportions of hospitalization (53.7% versus 4.0%; P < 0.0001) and emergency department visits (60.5% versus 9.7%; P < 0.0001). Conclusions High occurrence of several acute and chronic conditions and extensive health care use highlight the significant medical burden among patients with highly active NMO.

AB - Background Neuromyelitis optica (NMO) is characterized by unpredictable attacks on the optic nerves and spinal cord, causing accumulations of neurological disability that may lead to blindness and paralysis. We examined comorbidities and health care use among patients with highly active NMO, defined as at least two relapses within 12 months of the patient's first NMO encounter in the database. Methods This retrospective study of a US administrative claims database compared patients with highly active NMO to matched individuals without NMO. All outcomes, including Charlson Comorbidity Index (CCI) score, hospitalizations, and emergency department visits, were measured over the 12-month period following the patient's first NMO encounter in the database. Results A total of 1349 patients with NMO were identified. Of these, 134 had highly active NMO (80% female, mean age 45.6 years) and were matched to 670 non-NMO controls. Patients with highly active NMO had significantly greater comorbidity burden than non-NMO controls (mean CCI score: 4.1 versus 0.6; P < 0.0001) and greater proportions of hospitalization (53.7% versus 4.0%; P < 0.0001) and emergency department visits (60.5% versus 9.7%; P < 0.0001). Conclusions High occurrence of several acute and chronic conditions and extensive health care use highlight the significant medical burden among patients with highly active NMO.

KW - Disease burden

KW - Neurological disorders

KW - Neuromyelitis optica

KW - Real-world case-control study

UR - http://www.scopus.com/inward/record.url?scp=85036533389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036533389&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.11.022

DO - 10.1016/j.jns.2017.11.022

M3 - Article

C2 - 29249387

AN - SCOPUS:85036533389

VL - 384

SP - 96

EP - 103

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -